Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | SVP,Pres,Urology Pelvic Health | May 01, 2022 | May 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date May 01, 2022 · Filed May 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,461 |
Ending reported balance
After 2022-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-01 · Exercise / conversion · Acquired 2,062 · Balance 25,067 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-05-01 · Tax withholding · Disposed 606 · Balance 24,461 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2023-05-01 | Direct | 2,062 |
Reported balance
After 2022-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-01 · Exercise / conversion · Disposed 2,062 · Balance 2,062 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Paragon 28, Inc.
Report date April 21, 2025 · Filed April 21, 2025
Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 1
1 source rowRow 1 · 2025-04-21 · Disposition to issuer · Disposed 42,113 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor. F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor.
F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003183 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 20,368 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003183 · doc4.xml · derivative · entry 4 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,368 Underlying: Common Stock · 20,368 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 6,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003183 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,333 Underlying: Common Stock · 6,333 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002711 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,216 Underlying: Common Stock · 1,107 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 388 | $38.39 | $14,895.32 |
DisclosureSEC source: 0001225208-21-002711 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,539 Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002711 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| July 01, 2020 Filed Jul 9, 2020 14:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 854 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-009668 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855 Underlying: Common Stock · 854 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant. Read SEC document |
| July 01, 2020 Filed Jul 9, 2020 14:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 260 | $35.28 | $9,172.80 |
DisclosureSEC source: 0001225208-20-009668 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,269 Read SEC document |
| July 01, 2020 Filed Jul 9, 2020 14:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 854 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-009668 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007000 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,185 Underlying: Common Stock · 2,061 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 626 | $35.99 | $22,529.74 |
DisclosureSEC source: 0001225208-20-007000 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,675 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007000 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004165 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 1,018 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 309 | $37.39 | $11,553.51 |
DisclosureSEC source: 0001225208-20-004165 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,240 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004165 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · derivative · entry 9 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,227 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 359 | $42.62 | $15,300.58 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · nonDerivative · entry 6 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,531 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · nonDerivative · entry 5 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · derivative · entry 8 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159 Underlying: Common Stock · 1,159 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 331 | $42.62 | $14,107.22 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · nonDerivative · entry 4 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,663 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · nonDerivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · derivative · entry 7 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,337 Underlying: Common Stock · 778 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 264 | $42.62 | $11,251.68 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,835 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003299 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002844 · doc4.xml · derivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Stock · 16,592 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 4,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002844 · doc4.xml · derivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,447 Underlying: Common Stock · 4,447 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.